REG - EKF Diagnostics Hldg - Notice of Results

EKF Diagnostics HoldingsAnnouncement

25/08/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210825:nRSY6523Ja&default-theme=true

RNS Number : 6523J  EKF Diagnostics Holdings PLC  25 August 2021

 

 

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

 

Notice of Results

Investor briefing

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care
business, will announce its interim results for the six months ended 30 June
2021 on Tuesday 14 September 2021.

 

Investor briefing

EKF Diagnostics will be hosting a live online presentation open to all
investors on Wednesday 15 September 2021 at 5.15 pm (BST), via video
conference call. If you would like to register, please contact Walbrook PR on
020 7933 8780 or email ekf@walbrookpr.com (mailto:ekf@walbrookpr.com) .

 

 

 

 EKF Diagnostics Holdings plc                                               www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Christopher Mills, Non-executive Chairman                                  Tel: +44 (0) 29 2071 0570
 Julian Baines, CEO
 Richard Evans, FD & COO

 Singer Capital Markets                                                     Tel: 020 7496 3000
 Aubrey Powell / George Tzimas (Corporate Finance)

Tom Salvesen (Corporate Broking)

 Walbrook PR Limited              Tel: +44 (0) 20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Lianne Cawthorne  Mob: +44 (0) 7980 541 893 / +44 (0) 7584 391 303

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com/) )

EKF is a leading point-of-care diagnostics and central laboratory assay
manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose
and lactate analyzers in regular use across more than 100 countries. EKF
specializes in developing tests for use in anemia and diabetes diagnosis and
management, as well as providing a portfolio of reagents for use in clinical
chemistry analyzers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORFZGZRKDZGMZM